Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TAMOXIFEN CITRATE

4 general benefit · 4 not a benefit

Other products in the same Health Canada class (L02B, L02BA) — coverage varies; not interchangeable

  • Fulvestrant (Faslodex): general benefit
  • Abiraterone (Zytiga): general benefit
  • Anastrozole (Arimidex): general benefit
  • Bicalutamide (Casodex): general benefit, Not a benefit
  • Degarelix (Firmagon): general benefit
  • Exemestane (Aromasin): general benefit

3 more in the class list below

Apo-Tamox · DIN 00812404 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Tamox · DIN 00812404 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1989-12-31 · brand APO-TAMOX TAB 10MG · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Tamox: Formulary list price $0.1750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10664 · Verify on the e-Formulary ↗ (DIN 00812404)

Source record
DIN 00812404: Apo-Tamox Raw flags: sec3=Y Item: 100000040; group id 185; item number 0334; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1750; ministry $0.1750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00812404 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10664
Interchangeable products
Nolvadex · DIN 02048477 · not recorded Tamofen · DIN 01926624 · not recorded Teva-Tamoxifen · DIN 00851965 · $0.1750
Shortage status: resolved shortage (ended 2025-07-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00812404
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Tamoxifen · DIN 00851965 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Tamoxifen · DIN 00851965 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2011-06-01 · brand TEVA-TAMOXIFEN · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 10 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Tamoxifen: Formulary list price $0.1750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10790 · Verify on the e-Formulary ↗ (DIN 00851965)

Source record
DIN 00851965: Teva-Tamoxifen Raw flags: sec3=Y Item: 100000040; group id 185; item number 0334; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1750; ministry $0.1750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00851965 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10790
Interchangeable products
Apo-Tamox · DIN 00812404 · $0.1750 Nolvadex · DIN 02048477 · not recorded Tamofen · DIN 01926624 · not recorded
Shortage status: active shortage (reported 2024-04-03, last updated 2024-04-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00851965
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Tamox · DIN 00812390 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Tamox · DIN 00812390 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1989-12-31 · brand APO-TAMOX TAB 20MG · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 20 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Tamox: Formulary list price $0.3500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10762 · Verify on the e-Formulary ↗ (DIN 00812390)

Source record
DIN 00812390: Apo-Tamox Raw flags: sec3=Y Item: 100000056; group id 185; item number 0335; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3500; ministry $0.3500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00812390 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10762
Interchangeable products
Nolvadex D · DIN 02048485 · not recorded Tamofen · DIN 01926632 · not recorded Teva-Tamoxifen · DIN 00851973 · $0.3500
Shortage status: resolved shortage (ended 2024-07-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00812390
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Tamoxifen · DIN 00851973 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Tamoxifen · DIN 00851973 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2011-06-01 · brand TEVA-TAMOXIFEN · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 20 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Tamoxifen: Formulary list price $0.3500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10791 · Verify on the e-Formulary ↗ (DIN 00851973)

Source record
DIN 00851973: Teva-Tamoxifen Raw flags: sec3=Y Item: 100000056; group id 185; item number 0335; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3500; ministry $0.3500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00851973 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10791
Interchangeable products
Apo-Tamox · DIN 00812390 · $0.3500 Nolvadex D · DIN 02048485 · not recorded Tamofen · DIN 01926632 · not recorded
Shortage status: active shortage (reported 2024-02-07, last updated 2024-05-23) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00851973
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nolvadex · DIN 02048477 · 10mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-04-01 — choose a marketed DIN from the same-category list.Discontinued 2003-04-01 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-04-01 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-04-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nolvadex · DIN 02048477 Manufacturer: AstraZeneca; listing date 1996-10-01 Health Canada: Cancelled post market since 2003-04-01 · brand NOLVADEX TAB 10MG · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 10 MG · company Astrazeneca canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Nolvadex: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16822 · Verify on the e-Formulary ↗ (DIN 02048477)

Source record
DIN 02048477: Nolvadex Raw flags: notABenefit=Y, sec3=Y Item: 100000040; group id 185; item number 0334; lccId None; manufacturer id AZC Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02048477 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16822
Interchangeable products
Apo-Tamox · DIN 00812404 · $0.1750 Tamofen · DIN 01926624 · not recorded Teva-Tamoxifen · DIN 00851965 · $0.1750
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02048477
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-04-01 — choose a marketed DIN from the same-category list.

Tamofen · DIN 01926624 · 10mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-01-11 — choose a marketed DIN from the same-category list.Discontinued 2011-01-11 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-01-11 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2011-01-11 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tamofen · DIN 01926624 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2011-01-11 · brand TAMOFEN 10 · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 10 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Tamofen: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13043 · Verify on the e-Formulary ↗ (DIN 01926624)

Source record
DIN 01926624: Tamofen Raw flags: notABenefit=Y, sec3=Y Item: 100000040; group id 185; item number 0334; lccId None; manufacturer id SAV Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926624 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13043
Interchangeable products
Apo-Tamox · DIN 00812404 · $0.1750 Nolvadex · DIN 02048477 · not recorded Teva-Tamoxifen · DIN 00851965 · $0.1750
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926624
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2011-01-11 — choose a marketed DIN from the same-category list.

Nolvadex D · DIN 02048485 · 20mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-03-22 — choose a marketed DIN from the same-category list.Discontinued 2023-03-22 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-03-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-03-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nolvadex D · DIN 02048485 Manufacturer: AstraZeneca; listing date 1996-10-01 Health Canada: Cancelled post market since 2023-03-22 · brand NOLVADEX-D TAB 20MG · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 20 MG · company Astrazeneca canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Nolvadex D: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18639 · Verify on the e-Formulary ↗ (DIN 02048485)

Source record
DIN 02048485: Nolvadex D Raw flags: notABenefit=Y, sec3=Y Item: 100000056; group id 185; item number 0335; lccId None; manufacturer id AZC Source form: Tab; strength: 20mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02048485 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18639
Interchangeable products
Apo-Tamox · DIN 00812390 · $0.3500 Tamofen · DIN 01926632 · not recorded Teva-Tamoxifen · DIN 00851973 · $0.3500
Shortage status: discontinued (2023-03-21, reported by ASTRAZENECA CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02048485
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-03-22 — choose a marketed DIN from the same-category list.

Tamofen · DIN 01926632 · 20mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-01-14 — choose a marketed DIN from the same-category list.Discontinued 2011-01-14 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-01-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2011-01-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tamofen · DIN 01926632 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2011-01-14 · brand TAMOFEN 20 · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 20 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Tamofen: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13045 · Verify on the e-Formulary ↗ (DIN 01926632)

Source record
DIN 01926632: Tamofen Raw flags: notABenefit=Y, sec3=Y Item: 100000056; group id 185; item number 0335; lccId None; manufacturer id SAV Source form: Tab; strength: 20mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926632 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13045
Interchangeable products
Apo-Tamox · DIN 00812390 · $0.3500 Nolvadex D · DIN 02048485 · not recorded Teva-Tamoxifen · DIN 00851973 · $0.3500
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926632
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2011-01-14 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-TAMOX (tamoxifen tablets) is indicated for: • the adjuvant treatment of early breast cancer in women with estrogen receptor positive tumours. • the treatment of women with hormone responsive locally advanced/ metastatic breast cancer. 1.1 Pediatrics Pediatrics (< 18 years of age): the use of APO-TAMOX is not recommended in children, as safety and efficacy have not been established. https://pdf.hres.ca/dpd_pm/00081612.PDF PM date: OCT 17, 1989 Source product: APO-TAMOX TAB 20MG; DIN 00812390; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Tamoxifen · DIN 00851965 Shortage status: active shortage (reported 2024-04-03, last updated 2024-04-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00851965

Check this DIN again

Teva-Tamoxifen · DIN 00851973 Shortage status: active shortage (reported 2024-02-07, last updated 2024-05-23) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00851973

Check this DIN again

Nolvadex D · DIN 02048485 Shortage status: discontinued (2023-03-21, reported by ASTRAZENECA CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02048485

Check this DIN again

Other review policies

For Nolvadex, Tamofen, Nolvadex D: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026